8-K: PAVmed Inc. Creates Series C Convertible Preferred Stock in Debt Exchange

PAVmed Inc. exchanged $22.3 million of convertible notes for Series C Convertible Preferred Stock, aiming to improve its financial position and meet Nasdaq listing requirements.

Summary

• PAVmed Inc. has created a new series of preferred stock, designated as Series C Convertible Preferred Stock, with an authorized amount of 25,000 shares.
• A portion of these shares, specifically 22,347, were issued in exchange for approximately $22.3 million of senior convertible notes and accrued interest.
• The exchange was completed on January 17, 2025, as part of a broader effort to restructure the company's debt.
• The Series C Preferred Stock has a par value of $0.001 per share and ranks senior to common stock regarding dividends and liquidation preferences.
• Dividends on the preferred stock will accrue at a rate of 7.875% per annum, payable quarterly in shares of common stock or capitalized by increasing the stated value of the preferred shares.
• Each preferred share is convertible into common stock at a fixed price of $1.068, subject to adjustments for certain events.
• The conversion price can also be adjusted based on market conditions, with a floor price of $0.2136 per share.
• If all preferred shares were converted at the fixed price, approximately 20.9 million common shares would be issued, and if converted at the floor price, approximately 104.6 million common shares would be issued.
• The company has the option to redeem the preferred shares at 132.5% of the conversion amount under certain conditions.
• The company is also subject to certain covenants, including restrictions on incurring debt, issuing new securities, and making certain payments.

Sentiment

Score: 6

Explanation: The document indicates a positive step towards financial restructuring and Nasdaq compliance, but the potential for dilution and the restrictive covenants temper the overall sentiment. The company is taking action to improve its financial position, but there are still significant risks.

Positives

• The debt exchange reduces the company's outstanding convertible note principal by $22.3 million.
• The new preferred stock structure provides flexibility in managing dividend payments.
• The conversion feature of the preferred stock could lead to a significant increase in the company's equity base.
• The company has the option to redeem the preferred shares, providing a potential exit strategy.
• The exchange is a step towards regaining compliance with Nasdaq listing requirements.

Negatives

• The potential issuance of a large number of common shares upon conversion could dilute existing shareholders.
• The company is subject to various covenants that restrict its financial and operational flexibility.
• The preferred stock has a liquidation preference, which could disadvantage common shareholders in a liquidation event.
• The company is still subject to a Nasdaq hearing and there is no guarantee that they will regain compliance.
• The company is subject to a number of triggering events that could result in mandatory redemption of the preferred shares.

Risks

• The company may not be able to meet the financial covenants outlined in the agreement.
• The company may not be able to regain compliance with Nasdaq listing standards.
• The conversion of preferred stock could significantly dilute existing shareholders.
• The company is subject to various triggering events that could result in mandatory redemption of the preferred shares.
• The company's ability to raise additional capital may be limited by the terms of the preferred stock agreement.

Future Outlook

The company aims to regain compliance with Nasdaq listing standards through this debt exchange and the resulting increase in stockholders' equity. The conversion of the preferred stock could significantly increase the number of outstanding common shares.

Industry Context

This announcement is relevant to the biotech and medical device industry, where companies often use convertible debt and preferred stock to finance operations and growth. The restructuring of debt and the issuance of preferred stock are common strategies for companies facing financial challenges or seeking to improve their balance sheets.

Comparison to Industry Standards

• The use of convertible preferred stock is a common financing method for companies in the biotech and medical device sectors, particularly those that are pre-revenue or early-stage.
• The conversion price of $1.068 per share is relatively high compared to the current trading price of the common stock, suggesting a potential premium for the preferred stock holders.
• The floor price of $0.2136 per share provides a downside protection for the preferred stock holders, but also a potential for significant dilution for common stock holders.
• The 7.875% dividend rate is within the typical range for preferred stock in this sector, but the payment in common stock or capitalization provides flexibility for the company.
• The 132.5% redemption premium is a common feature in preferred stock agreements, providing an incentive for investors and a cost for the company if it chooses to redeem the shares.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted to common stock.
• Creditors have exchanged a portion of their debt for preferred stock, potentially improving the company's financial stability.
• Employees may be affected by the company's financial performance and compliance with listing standards.
• Customers and suppliers may be indirectly affected by the company's financial health and operational changes.

Next Steps

• The company needs to continue to work towards regaining compliance with Nasdaq listing standards.
• The company needs to manage its financial covenants and operational restrictions.
• The company needs to monitor the conversion of the preferred stock and its impact on the share structure.

Key Dates

Keywords

Series C Convertible Preferred Stock, Convertible Notes, Debt Exchange, Preferred Stock, Common Stock, Conversion Price, Nasdaq Listing, Financial Covenants, Redemption, Dilution